British drugmaker Astra Zeneca announced Monday it has started Phase 3 trials of its coronavirus vaccine candidate in the United States . 
AZD 1222 becomes the third vaccine to enter large scale trials in the United States , after vaccines made by Moderna and Pfizer/Bio NTech . 
For the US trial , Astra Zeneca said in a statement that it is " recruiting up to 30,000 adults aged 18 years or over from diverse racial , ethnic and geographic groups who are healthy or have stable underlying medical conditions , including those living with HIV , and who are at increased risk of infection from the SARS Co V 2 virus . " 
Participants will receive two active or placebo doses , spaced two weeks apart . 
The trial will assess safety and efficacy in all participants â€“ a subset of 3,000 participants will be assessed for local and systemic reactions and immune responses . 
Currently , Phase 3 trials of AZD1222 are going on in the UK , Brazil and South Africa . 
Trials are also planned for Japan and Russia . 
In total , Phase 3 clinical trial for AZD 1222 will enroll up to 50,000 participants globally . 
Results from the late stage trials are anticipated later this year . 
The trial is funded by the Biomedical Advanced Development Authority , which is run by the US Department of Health and Human Services and the National Institute of Allergy and Infectious Diseases . 
